THE CLINICAL IMPACT OF RIVAROXABAN TO CHINESE AT ATRIAL FIBRILLATION PATIENTS RESULTS FROM A SIMPLE COMMUNICATION TOOL

被引：0
|
作者：
Yang, L. [1 ]
Wu, J. J. [2 ]
Zhu, G. [2 ]
Evers, T. [3 ]
机构：
[1] Peking Univ, Beijing 100871, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Bayer Pharma AG, Wuppertal, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV143
引用
收藏
页码：A497 / A497
页数：1
相关论文
共 50 条
  • [41] Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF
    Girgis, I. G.
    Patel, M. R.
    Peters, G. R.
    Moore, K. T.
    Mahaffey, K. W.
    Nessel, C. C.
    Halperin, J. L.
    Califf, R. M.
    Fox, K. A. A.
    Becker, R. C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (08): : 917 - 927
  • [42] Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis
    Ito, Hiroshi
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 154 - 155
  • [43] Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes
    Wang, Zhe
    Zhu, Long-Yang
    Yu, Lu-Yao
    Chen, Wen-Qian
    Chen, Yi-Nong
    Li, Qing
    Liu, Ying
    Jiao, Si-Qi
    Zhai, Zhen-Guo
    Zhao, Li
    Sun, Yi-Hong
    THROMBOSIS RESEARCH, 2022, 218 : 189 - 191
  • [44] Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
    Guo, Yutao
    Kotalczyk, Agnieszka
    Wang, Yutang
    Lip, Gregory Y. H.
    EUROPACE, 2022, 24 (07): : 1076 - 1083
  • [45] Occlusion of Left Atrial Appendage in Patients With Atrial Fibrillation: Clinical Results From the LAARGE Registry
    Lewalter, Thorsten W.
    Brachmann, Johannes
    Akin, Ibrahim
    Sievert, Horst
    Geist, Volker
    Zeymer, Uwe
    Erkapic, Damir
    Mudra, Harald
    Pleger, Sven
    Hochadel, Matthias
    Senges, Jochen
    CIRCULATION, 2017, 136
  • [46] Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice
    Zeymer, Uwe
    Toelg, Ralph
    Wienbergen, Harm
    Hobbach, Hans-Peter
    Cuneo, Alessandro
    Bekeredjian, Raffi
    Ritter, Oliver
    Hailer, Birgit
    Hertting, Klaus
    Hennersdorf, Marcus
    Scholtz, Werner
    Lanzer, Peter
    Mudra, Harald
    Schwefer, Markus
    Schwimmbeck, Peter-Lothar
    Liebetrau, Christoph
    Thiele, Holger
    Claas, Christoph
    Riemer, Thomas
    Zahn, Ralf
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 189 : 31 - 37
  • [47] Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
    Xiao-qin Liu
    Yu-fei Zhang
    Hong-yan Ding
    Ming-ming Yan
    Zheng Jiao
    Ming-kang Zhong
    Chun-lai Ma
    Acta Pharmacologica Sinica, 2022, 43 : 2723 - 2734
  • [48] Impact of gender: Rivaroxaban for patients with atrial fibrillation in theXANTUSreal-world prospective study
    Camm, A. John
    Amarenco, Pierre
    Haas, Sylvia
    Bach, Miriam
    Kirchhof, Paulus
    Kuhls, Silvia
    Lambelet, Marc
    Turpie, Alexander G. G.
    CLINICAL CARDIOLOGY, 2020, 43 (12) : 1405 - 1413
  • [49] Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
    Chan, Kevin E.
    Edelman, Elazer R.
    Wenger, Julia B.
    Thadhani, Ravi I.
    Maddux, Franklin W.
    CIRCULATION, 2015, 131 (11) : 972 - 979
  • [50] Poor Correlation of Rivaroxaban Concentration with the Routine Coagulation Screening Test in Chinese Patients with Atrial Fibrillation
    He, Jiake
    Zhu, Bo
    Shen, Yang
    Hu, Jianping
    Hong, Kui
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2023, 2023
12345